menu
    • menu

    Company profile for Prilenia therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Prilenia is a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is a world-renowned scientist in Huntington Disease research. He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS....
    Prilenia is a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is a world-renowned scientist in Huntington Disease research. He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS. The company has recently raised $62.5M in a Series A financing round to launch the planned HD and ALS late-stage clinical trials.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Prilenia therapeuticsNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Gooimeer 2/35, 1411 DC NAARDEN, Netherlands
    Telephone
    Telephone
    +972-77-5558482
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.prilenia.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/prilenia/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Prilenia Ferrer Enroll First Patient In PREVAiLS Ph3 ALS Study
    Prilenia Ferrer Enroll First Patient In PREVAiLS Ph3 ALS Study

    30 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260330646991/en/Prilenia-and-Ferrer-Announce-First-Participant-Enrolled-in-the-PREVAiLS-Phase-3-Study-of-Pridopidine-in-ALS

    BUSINESSWIRE
    30 Mar 2026
    Share Share
    Prilenia, Ferrer To Begin 'Prevails' Phase 3 ALS Study
    Prilenia, Ferrer To Begin 'Prevails' Phase 3 ALS Study

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251211232354/en/Prilenia-and-Ferrer-Announce-FDA-Clearance-to-Start-the-PREVAiLS-Pivotal-Phase-3-Study-with-Pridopidine-in-ALS

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    Prilenia & Ferrer Share Data on Pridopidine in Huntington Disease
    Prilenia & Ferrer Share Data on Pridopidine in Huntington Disease

    10 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251010035801/en/Prilenia-and-Ferrer-to-Share-New-Data-and-Analyses-of-Pridopidines-Impact-on-Huntingtons-Disease-at-the-Huntington-Study-Group-HSG-Congress

    BUSINESSWIRE
    10 Oct 2025
    Share Share
    Pridopidine Phase 3 ALS Study Revealed At NEALS 2025 Conference
    Pridopidine Phase 3 ALS Study Revealed At NEALS 2025 Conference

    06 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251006420172/en/Pridopidine-Pivotal-Phase-3-ALS-Study-Unveiled-at-NEALS-2025-Annual-Meeting

    BUSINESSWIRE
    06 Oct 2025
    Share Share
    Prilenia & Ferrer today announced Ph3 Data on Pridopidine
    Prilenia & Ferrer today announced Ph3 Data on Pridopidine

    05 Sep 2025

    // PRESS RELEASE

    https://www.ferrer.com/en/Nature-Medicine-Publishes-Phase-3-Data-on-Pridopidine-in-Early-Stage-Huntingtons-Disease-Highlighting-Impact-on-Clinical-Progression

    PRESS RELEASE
    05 Sep 2025
    Share Share
    Prilenia, Ferrer Give EU Update on Pridopidine in Huntington
    Prilenia, Ferrer Give EU Update on Pridopidine in Huntington

    25 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250725635763/en/Prilenia-and-Ferrer-Provide-Update-on-European-Regulatory-Process-for-Pridopidine-in-Huntingtons-Disease

    BUSINESSWIRE
    25 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search